Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
Reads0
Chats0
TLDR
Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.About:
This article is published in The Lancet.The article was published on 2016-04-02. It has received 713 citations till now. The article focuses on the topics: Pemetrexed & Pleural effusion.read more
Citations
More filters
Journal Article
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
Journal ArticleDOI
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
TL;DR: The roles of VEGF and ANG2 are outlined, and ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes are suggested, and avenues of future research are highlighted.
Journal ArticleDOI
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen,Erwei Song +1 more
TL;DR: The progress made to date and the remaining challenges in bringing CAF-targeted therapies to the clinic are highlighted and the relevant translational advances and potential therapeutic strategies that target CAFs for cancer treatment are highlighted.
Journal ArticleDOI
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott J. Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gérard Zalcman +20 more
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.
Journal ArticleDOI
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy.
TL;DR: Current understanding of the tumorigenic significance, origin, and heterogeneity of CAFs, as well as the roles of different CAFs subtypes in distinct immune cell types are described.
References
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
A multiple testing procedure for clinical trials.
TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Journal Article
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
Journal ArticleDOI
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang,James J. Rusthoven,James T. Symanowski,Claude Denham,E. Kaukel,Pierre Ruffié,Ulrich Gatzemeier,Michael Boyer,Salih Emri,Christian Manegold,Clet Niyikiza,Paolo Paoletti +11 more
TL;DR: Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Interpreting the significance of changes in health-related quality-of-life scores.
TL;DR: The significance of changes in QLQ-C30 scores can be interpreted in terms of small, moderate, or large changes in quality of life as reported by patients in the SSQ.
Related Papers (5)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno,Eric Stawiski,Leonard D. Goldstein,Steffen Durinck,Assunta De Rienzo,Zora Modrusan,Florian Gnad,Thong T. Nguyen,Bijay S. Jaiswal,Lucian R. Chirieac,Daniele Sciaranghella,Nhien Dao,Corinne E. Gustafson,Kiara J. Munir,Jason A. Hackney,Amitabha Chaudhuri,Ravi Gupta,Joseph Guillory,Karen Toy,Connie Ha,Ying-Jiun Chen,Jeremy Stinson,Subhra Chaudhuri,Na Zhang,Thomas D. Wu,David J. Sugarbaker,Frederic J. de Sauvage,William G. Richards,Somasekar Seshagiri +28 more
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio,Arnaud Scherpereel,Luana Calabrò,Joachim G.J.V. Aerts,Susana Cedres Perez,Alessandra Bearz,Kristiaan Nackaerts,Dean A. Fennell,Dariusz M. Kowalski,Anne S. Tsao,Paul D. Taylor,Federica Grosso,Scott J. Antonia,Anna K. Nowak,Anna K. Nowak,Maria Taboada,Martina Puglisi,Paul K. Stockman,Hedy L. Kindler +18 more